What challenges exist in developing miRNA sponges for clinical use?
Despite their potential, several challenges must be overcome to develop miRNA sponges for clinical use. One major challenge is the delivery of these sponges to the tumor site. Effective delivery systems, such as nanoparticles or viral vectors, are needed to ensure that the sponges reach their target cells. Additionally, the stability of miRNA sponges in the bloodstream and their potential immunogenicity are concerns that require careful consideration. Finally, extensive preclinical and clinical testing is needed to evaluate the safety and efficacy of miRNA sponges in cancer patients.
